Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.

doi:10.1200/JCO.2021.39.15_suppl.e13069

HFCAS OpenIR

	Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
	Wang, Rong ; Wang, Xiaojia ; Chen, Zhan-Hong ; Niu, Jin ; Huang, Yuan ; Pan, Jiani ; Ye, Weiwu ; Cao, Wenming
	2021-05-20
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.e13069
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province, China
项目资助者	National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province, China
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000708120300179
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/126645
专题	中国科学院合肥物质科学研究院
作者单位	1.Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 2.Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China 3.Zhejiang Canc Hosp, Hangzhou, Peoples R China 4.Burning Rock Biotech, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Rong,Wang, Xiaojia,Chen, Zhan-Hong,et al. Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Wang, Rong.,Wang, Xiaojia.,Chen, Zhan-Hong.,Niu, Jin.,Huang, Yuan.,...&Cao, Wenming.(2021).Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Wang, Rong,et al."Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).